Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Mirum Pharmaceuticals's current 3-Year Share Buyback Ratio was -12.00%.
The historical rank and industry rank for Mirum Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:
FRA:08D'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8 Med: -16.2 Max: -9.9
Current: -12
During the past 8 years, Mirum Pharmaceuticals's highest 3-Year Share Buyback Ratio was -9.90%. The lowest was -17.80%. And the median was -16.20%.
FRA:08D's 3-Year Share Buyback Ratio is ranked worse than 50.68% of 1184
companies
in the Biotechnology industry
Industry Median: -11.6
vs FRA:08D: -12.00
Mirum Pharmaceuticals (FRA:08D) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Mirum Pharmaceuticals 3-Year Share Buyback Ratio Related Terms
FRA:08D vs DNTH, COGT, PTCT: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's 3-Year Share Buyback Ratio falls into.
Mirum Pharmaceuticals 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -12.00 mean?
Mirum Pharmaceuticals (FRA:08D) has a 3-Year Share Buyback Ratio of -12.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #600 out of 1184 companies in the Biotechnology industry, placing it in the top 50.7%.
Is Mirum Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Mirum Pharmaceuticals' current 3-Year Share Buyback Ratio is -12.00. Based on the distribution chart, Mirum Pharmaceuticals ranks #600 out of 1184 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' 3-Year Share Buyback Ratio compare to DNTH and COGT?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #600 out of 1184 companies for 3-Year Share Buyback Ratio. This places Mirum Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current 3-Year Share Buyback Ratio is -12.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (FRA:08D) is currently considered Fairly Valued. The stock's GF Value™ is €74.28, compared to a current price of €78.04 — trading 5.1% above its estimated fair value. The current 3-Year Share Buyback Ratio is -12.00. Mirum Pharmaceuticals' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Mirum Pharmaceuticals (FRA:08D), the current 3-Year Share Buyback Ratio is -12.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (FRA:08D) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of €78.04 is trading 5.1% above its estimated GF Value™ of €74.28.
GuruFocus considers Mirum Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:08D:
3-Year Share Buyback Ratio: -12.00
GF Value™: €74.28 vs. price of €78.04 (5.1% above fair value)
No single metric tells the full story. See the FRA:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on therapies for rare and orphan liver diseases. Its lead product, Livmarli (maralixibat), is an orally administered ileal bile acid transporter inhibitor approved for cholestatic pruritus in patients with Alagille syndrome and for progressive familial intrahepatic cholestasis. The company also markets Cholbam (cholic acid) for bile acid synthesis disorders and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. Mirum is developing volixibat for adult cholestatic liver conditions, including primary sclerosing cholangitis and primary biliary cholangitis. Its customers are primarily specialty pharmacies, hospitals, and healthcare providers in the United States and Europe, where it sells directly and through distributors. Revenue comes mainly from product sales of its approved medicines, supplemented by licensing and collaboration arrangements.
52GF Score
Get the complete analysis for FRA:08D
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:08D has been successfully added to your 
